Project RHO-CURE – Development of pharmacological treatment options to halt retinal degeneration caused by dominant…

Basic data

Acronym:
RHO-CURE
Title:
Development of pharmacological treatment options to halt retinal degeneration caused by dominant rhodopsin mutations
Duration:
15/09/2018 to 14/03/2021
Abstract / short description:
Inherited retinal degenerations (RD) are blinding diseases caused by mutations affecting the light sensing photoreceptors. This leads to an irreversible loss of photoreceptors and vision, and to date, these diseases are still untreatable. Two metabolic networks stand out as particularly interesting for therapy development, namely disturbances in proteostasis and aberrant cGMP-signaling. Mutations causing a disruption of the phototransduction cascade typically result in a dysregulation of cGMP-signaling, while mutations affecting the proper folding of proteins cause pertinent cellular stress. Mutations in the rhodopsin gene stand out because they may activate both degenerative pathways. Here, we are proposing to develop treatment approaches addressing the degenerative effects of rhodopsin mutations in their entirety. The objective is to build a preclinical rationale to restore protein homeostasis and/or inhibiting cGMP-signaling to specifically treat the Ile-256del mutation in the rhodopsin gene.

Involved staff

Managers

Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine
Research Center for Ophthalmology
Center for Ophthalmology, Hospitals and clinical institutes, Faculty of Medicine

Local organizational units

Research Center for Ophthalmology
Center for Ophthalmology
Hospitals and clinical institutes, Faculty of Medicine

Funders

Tübingen, Baden-Württemberg, Germany
Help

will be deleted permanently. This cannot be undone.